These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9706135)
1. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135 [TBL] [Abstract][Full Text] [Related]
2. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833 [TBL] [Abstract][Full Text] [Related]
3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]
4. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells]. Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079 [TBL] [Abstract][Full Text] [Related]
5. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009 [TBL] [Abstract][Full Text] [Related]
6. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety. Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333 [TBL] [Abstract][Full Text] [Related]
7. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783 [TBL] [Abstract][Full Text] [Related]
8. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438 [TBL] [Abstract][Full Text] [Related]
9. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295 [TBL] [Abstract][Full Text] [Related]
10. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514 [TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595 [TBL] [Abstract][Full Text] [Related]
12. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells. Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422 [TBL] [Abstract][Full Text] [Related]
13. [Tumor RNA introduction into dendritic cells and Epstein-Barr virus transformed B cells]. Minami K; Yamaguchi Y; Ohshita A; Kawabuchi Y; Shimizu K; Ohta K; Hihara J; Miyahara E; Toge T Gan To Kagaku Ryoho; 2003 Oct; 30(11):1813-6. PubMed ID: 14619527 [TBL] [Abstract][Full Text] [Related]
15. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response. Sugano M; Conway TF; Kelleher RJ; Sugiyama Y; Chen FA; Bankert RB; Bernstein SH J Exp Clin Cancer Res; 2001 Jun; 20(2):175-82. PubMed ID: 11484971 [TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro]. Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063 [TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268 [TBL] [Abstract][Full Text] [Related]
18. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells. Konttinen YT; Bluestein HG; Zvaifler NJ J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749 [TBL] [Abstract][Full Text] [Related]
19. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen]. Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based therapy for mantle cell lymphoma. Munger CM; Vose JM; Joshi SS Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]